🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT06990867
Recruiting Phase 2/3

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

NCT06990867 · tracked via the Priya Life Science USA tracker
Sponsor
Corxel Pharmaceuticals
Phase
Phase 2/3
Started
2025-05-15
Last updated
2026-03-13

Condition(s) studied

Acute Ischemic Stroke

Investigational drug(s) / intervention(s)

JX10Placebo

JX10: JX10 is a thrombolytic agent.

Placebo: Placebo is being used as the comparator.

Study summary

The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours.

The main question the study aims to answer are:

1. JX10 improves functional outcomes as measured by the modified Rankin Scale score when compared with placebo following AIS.
2. Risk of symptomatic intracranial hemorrhage of JX10 in participants with AIS.

During Part 1, participants will be randomized to JX 10 (1mg/kg, 3 mg/kg) or placebo. During Part 2, participants will receive JX10 (optimal dose chosen from Part 1) or placebo.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥ 18 and ≤ 90 years old. 2. Acute ischemic stroke with compatible clinical presentation and symptomatic high grade or complete occlusion of the intracranial internal carotid, M1, M2 or distal branches of the middle cerebral artery (MCA), anterior cerebral artery (ACA), or posterior cerebral artery (PCA). 3. Radiographic evidence of salvageable tissue. 4. Pre-treatment score of NIHSS ≥ 5. Exclusion Criteria: 1. Radiographic findings pre-randomization of any of the following: 1. Large core infarction, or 2. Occlusion in more than 1 vascular territory, or 3. Significant mass effect or clinically significant cerebral edema, or 4. Evidence of acute intracranial or extracranial hemorrhage, intracranial tumor (except small meningioma), neoplasm, or arteriovenous malformation), or 5. Clinical history, past imaging, or clinical judgement suggests that the intracranial occlusion is chronic. 2. Medical history or active clinically significant bleeding, lesions, or conditions (at the investigator's judgement) considered to be of significant risk for major bleeding. 3. Severe, uncontrolled hypertension (systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg) that cannot be controlled with antihypertensive therapy. 4. Known bleeding diathesis (hereditary or acquired) or any significant coagulopathy. Specifically, platelet count \< 100,000/μL, international normalized ratio \> 1.7, aPTT \> 40 seconds, or prothrombin time \> 15 seconds. 5. Major trauma, surgery, or invasive procedures. 6. Pre-existing medical, neurological, or psychiatric disease that would confound the neurological or functional evaluations of this study. 7. Pre-treatment blood glucose \> 400 mg/dL (22.20 mmol/L) or Pre-treatment blood glucose \< 50 mg/dL (2.78 mmol/L) unless it is corrected prior to study treatment administration. Participants with subsequently normalized blood glucose levels may be considered for inclusion, per Investigator judgement.

Primary outcome measure(s)

Trial sites (83)

FacilityCityRegionStatus
Corxel Investigational Site Long Beach California Recruiting
Corxel Investigational Site Sacramento California Recruiting
Corxel Investigational Site Colorado Springs Colorado Recruiting
Corxel Investigational Site Washington D.C. District of Columbia Recruiting
Corxel Investigational Site Delray Beach Florida Recruiting
Corxel Investigational Site Chicago Illinois Recruiting
Corxel Investigational Site Wichita Kansas Recruiting
Corxel Investigational Site Baltimore Maryland Recruiting
Corxel Investigational Site Kalamazoo Michigan Recruiting
Corxel Investigational Site Traverse City Michigan Recruiting
Corxel Investigational Site St Louis Missouri Recruiting
Corxel Investigational Site Great Neck New York Recruiting
Corxel Investigational Site New York New York Recruiting
Corxel Investigational Site Toledo Ohio Recruiting
Corxel Investigational Site Tulsa Oklahoma Recruiting
Corxel Investigational Site Dallas Texas Recruiting
Corxel Investigational Site Houston Texas Recruiting
Corxel Investigational Site Ghent Belgium Recruiting
Corxel Investigational Site Blagoevgrad Bulgaria Recruiting
Corxel Investigational Site Burgas Bulgaria Recruiting
Corxel Investigational Site Pleven Bulgaria Recruiting
Corxel Investigational Site Plovdiv Bulgaria Recruiting
Corxel Investigational Site Sofia Bulgaria Recruiting
Corxel Investigational Site Edmonton Canada Recruiting
Corxel Investigational Site Kingston Canada Recruiting
Corxel Investigational Site Baotou China Recruiting
Corxel Investigational Site Beijing China Recruiting
Corxel Investigational Site Beijing China Recruiting
Corxel Investigational Site Changchun China Recruiting
Corxel Investigational Site Guangzhou China Recruiting
Corxel Investigational Site, Harbin China Recruiting
Corxel Investigational Site Harbin China Recruiting
Corxel Investigational Site Kaili China Recruiting
Corxel Investigational Site Linfen China Recruiting
Corxel Investigational Site Shanghai China Recruiting
Corxel Investigational Site Shenyang China Recruiting
Corxel Investigational Site Suzhou China Recruiting
Corxel Investigational Site Weifang China Recruiting
Corxel Investigational Site Xuzhou China Recruiting
Corxel Investigational site Lille France Recruiting

+ 43 more sites — see the full list on the official registry below.

More Corxel Pharmaceuticals trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06990867 on ClinicalTrials.gov ↗ ← All trials in the USA